Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond

12 Apr 2021

Abstract excerpt

B-cell lymphoma 6 (BCL6) is a master regulator of germinal center formation that produce antibody-secreting plasma cells and memory B-cells for sustained immune responses. The BTB domain of BCL6 (BCL6 BTB ) forms a homodimer that mediates transcriptional repression by recruiting its corepressor proteins to form a biologically functional transcriptional complex. The protein–protein interaction (PPI) between the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33844535
DOI: 10.1021/acs.jmedchem.0c01686

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and BeyondPMID 33844535Read ↗

BCL6 as a therapeutic target for lymphoma.Semantic proximity Read ↗

Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomasSemantic proximity Read ↗

Novel Small Molecule DZ-865B Effectively Degrades BCL6, Promotes Apoptosis and Reduces Proliferation of Diffuse Large B-Cell Lymphoma CellsSemantic proximity Read ↗

B Cell Lymphoma 6 (BCL6): A Conserved Regulator of Immunity and BeyondSemantic proximity Read ↗

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphomaSemantic proximity Read ↗

A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivoSemantic proximity Read ↗

Diffuse large B cell lymphoma: molecular targeted therapy.Semantic proximity Read ↗

Molecular Pathogenesis of Non-Hodgkin's Lymphoma: the Role of Bcl-6Semantic proximity Read ↗

BTK Inhibitors and BTK Degraders for the Treatment of Mantle Cell Lymphoma - Current Status and PerspectivesSemantic proximity Read ↗

B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric CancersSemantic proximity Read ↗

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future DirectionsSemantic proximity Read ↗

Altered pathways and targeted therapy in double hit lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.